Clemens Decristoforo

68Ga-DOTA-Tyr3-Octreotide PET in Neuroendocrine Tumors: Comparison with Somatostatin Receptor Scintigraphy and CT

Michael Gabriel, Clemens Decristoforo, Dorota Kendler et al. · Journal of Nuclear Medicine · 2007 · 1K citations · Full text

Medicine, Nuclear Medicine, Oncology +17

Guideline for PET/CT imaging of neuroendocrine neoplasms with 68Ga-DOTA-conjugated somatostatin receptor targeting peptides and 18F–DOPA

Murat Fani Bozkurt, Irene Virgolini, Soňa Balogová et al. · European Journal of Nuclear Medicine and Molecular Imaging · 2017 · 488 citations · Full text

Medicine, Nuclear Medicine, Oncology +17

68Ga-PSMA-11 PET/CT in primary staging of prostate cancer: PSA and Gleason score predict the intensity of tracer accumulation in the primary tumour

Christian Uprimny, Alexander Kroiss, Clemens Decristoforo et al. · European Journal of Nuclear Medicine and Molecular Imaging · 2017 · 342 citations

Medicine, Nuclear Medicine, Oncology +17

68Ga-PSMA PET/CT for restaging recurrent prostate cancer: which factors are associated with PET/CT detection rate?

Francesco Ceci, Christian Uprimny, Bernhard Nilica et al. · European Journal of Nuclear Medicine and Molecular Imaging · 2015 · 260 citations

Medicine, Nuclear Medicine, Radiology +16

Bone Metastases in Patients with Neuroendocrine Tumor: ⁶⁸Ga-DOTA-Tyr³-Octreotide PET in Comparison to CT and Bone Scintigraphy

Daniel Putzer, Michael Gabriel, Benjamin Henninger et al. · Journal of Nuclear Medicine · 2009 · 218 citations · Full text

Medicine, Nuclear Medicine, Oncology +17